中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 12
Dec.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(12): 2839-2844

Value of Model for End-Stage Liver Disease score and albumin-bilirubin score combined with β2-microglobulin in predicting liver cirrhosis with acute kidney injury

DOI: 10.3969/j.issn.1001-5256.2023.12.014

  • Department of Gastroenterology，The First Affiliated Hospital of Zhengzhou University，Zhengzhou 450000，China

Research funding:

Medical Science and Technology Project of Henan Province (SBGJ2018036)

More Information
  • Corresponding author: WANG Hong， wanghong0930@163.com （ORCID： 0009-0002-1977-3612）
  • Received Date: 2023-03-08
  • Accepted Date: 2023-04-14
  • Published Date: 2023-12-12
    Abstract
  •   Objective  To investigate the value of combined determination of Model for End-Stage Liver Disease （MELD） score， albumin-bilirubin （ALBI） score， and β2-microglobulin in the diagnosis of liver cirrhosis with acute kidney injury （AKI）.  Methods  Clinical data were collected from 258 patients with liver cirrhosis who attended The First Affiliated Hospital of Zhengzhou University from October 2019 to October 2022， and according to the presence or absence of AKI， they were divided into AKI group with 117 patients and non-AKI group with 141 patients. The changes in each index were compared between the two groups and between the patients with different stages of kidney injury. The independent samples t-test was used for comparison of normally distributed continuous data between two groups， and a one-way analysis of variance was used for comparison between multiple groups； the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups， and the Kruskal-Wallis H test was used for comparison between multiple groups； the chi-square test was used for comparison of categorical data between groups. The receiver operating characteristic （ROC） curve was plotted to evaluate the efficacy of each index in the diagnosis of liver cirrhosis with AKI.  Results  Compared with the non-AKI group， the AKI group had significantly higher age （t=2.307， P=0.022）， proportion of patients with hepatic encephalopathy （χ2=18.064， P<0.001） or with spontaneous peritonitis （χ2=16.397， P<0.001）， mortality rate （χ2=45.251， P<0.001）， levels of creatinine （Z=-8.737， P<0.001） and β2-microglobulin （Z=-8.829， P<0.001）， and scores of CTP （Z=-4.058， P<0.001）， ALBI （t=2.563， P=0.011）， and MELD （Z=-5.628， P<0.001）， as well as a significantly shorter length of hospital stay （Z=-3.391， P=0.001）. There were significant differences in creatinine， β2-microglobulin， MELD score， and ALBI score between the patients with stage 1， 2 or 3 AKI （P<0.05）， while there was no significant difference in CTP score between these three groups （P>0.05）. The combined determination of ALBI score， MELD score， and β2-microglobulin had an area under the ROC curve （AUC） of 0.837 （95% confidence interval ［CI］： 0.782 — 0.892）， with a sensitivity of 75.2% and a specificity of 90.8%； ALBI score combined with MELD score had an AUC of 0.700 （95%CI： 0.636 — 0.764）， ALBI score combined with β2 microglobulin had an AUC of 0.823 （95%CI： 0.765 — 0.881）， and MELD combined with and β2 microglobulin had an AUC of 0.835 （95%CI： 0.779 — 0.890）， suggesting that combined determination of ALBI score， MELD score， and β2-microglobulin had a better diagnostic efficacy than ALBI score， MELD score， or β2-microglobulin used alone or in pairs， as well as a better diagnostic efficacy than creatinine.  Conclusion  Combined determination of ALBI score， MELD score， and β2-microglobulin has a relatively high value in the diagnosis of liver cirrhosis with AKI.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    PIANO S, ROSI S, MARESIO G, et al. Evaluation of the acute kidney injury network criteria in hospitalized patients with cirrhosis and ascites[J]. J Hepatol, 2013, 59( 3): 482- 489. DOI: 10.1016/j.jhep.2013.03.039.
    [2]
    MACDONALD AJ, NADIM MK, DURAND F, et al. Acute kidney injury in cirrhosis: Implications for liver transplantation[J]. Curr Opin Crit Care, 2019, 25( 2): 171- 178. DOI: 10.1097/MCC.0000000000000590.
    [3]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [4]
    FLAMM SL, WONG F, AHN J, et al. AGA clinical practice update on the evaluation and management of acute kidney injury in patients with cirrhosis: Expert review[J]. Clin Gastroenterol Hepatol, 2022, 20( 12): 2707- 2716. DOI: 10.1016/j.cgh.2022.08.033.
    [5]
    WONG F, O’LEARY JG, REDDY KR, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection[J]. Gastroenterology, 2013, 145( 6): 1280- 1288.e1. DOI: 10.1053/j.gastro.2013.08.051.
    [6]
    GUPTA K, BHURWAL A, LAW C, et al. Acute kidney injury and hepatorenal syndrome in cirrhosis[J]. World J Gastroenterol, 2021, 27( 26): 3984- 4003. DOI: 10.3748/wjg.v27.i26.3984.
    [7]
    LEE HA, SEO YS. Current knowledge about biomarkers of acute kidney injury in liver cirrhosis[J]. Clin Mol Hepatol, 2022, 28( 1): 31- 46. DOI: 10.3350/cmh.2021.0148.
    [8]
    HUO QQ, DONG WS, GAO Y, et al. Effect of β2-microglobulin in evaluating the severity and prognosis of brain injury: A clinical study[J]. BMC Neurol, 2022, 22( 1): 327. DOI: 10.1186/s12883-022-02850-8.
    [9]
    CHEN LL, HAN W, LIU JJ, et al. Research advances in the biomarkers for the early diagnosis of hepatorenal syndrome[J]. J Clin Hepatol, 2018, 34( 11): 2448- 2452. DOI: 10.3969/j.issn.1001-5256.2018.11.040.

    陈兰兰, 韩文, 刘京京, 等. 肝肾综合征早期生物学标志物的研究进展[J]. 临床肝胆病杂志, 2018, 34( 11): 2448- 2452. DOI: 10.3969/j.issn.1001-5256.2018.11.040.
    [10]
    WANG RJ, CHEN J, DING F, et al. Renal tubular injury induced by glyphosate combined with hard water: The role of cytosolic phospholipase A2[J]. Ann Transl Med, 2021, 9( 2): 130. DOI: 10.21037/atm-20-7739.
    [11]
    WANG R, HU HT, HU S, et al. β2-microglobulin is an independent indicator of acute kidney injury and outcomes in patients with intracerebral hemorrhage[J]. Medicine, 2020, 99( 8): e19212. DOI: 10.1097/MD.0000000000019212.
    [12]
    ZHANG FM, LIU SY. Application of combined detection of cystatin C and β2-microglobulin in patients with acute kidney injury secondary to liver cirrhosis[J]. Chin J Lab Diagn, 2022, 26( 9): 1346- 1348. DOI: 10.3969/j.issn.1007-4287.2022.09.022.

    张凤美, 刘树业. 胱抑素C、β2-微球蛋白联合检测在肝硬化继发急性肾损伤患者中的应用[J]. 中国实验诊断学, 2022, 26( 9): 1346- 1348. DOI: 10.3969/j.issn.1007-4287.2022.09.022.
    [13]
    TEJEDOR M, SELZNER N, BERENGUER M. Are MELD and MELDNa still reliable tools to predict mortality on the liver transplant waiting list?[J]. Transplantation, 2022, 106( 11): 2122- 2136. DOI: 10.1097/TP.0000000000004163.
    [14]
    RUF A, DIRCHWOLF M, FREEMAN RB. From Child-Pugh to MELD score and beyond: Taking a walk down memory lane[J]. Ann Hepatol, 2022, 27( 1): 100535. DOI: 10.1016/j.aohep.2021.100535.
    [15]
    LINS PRG, NARCISO RC, FERRAZ LR, et al. Modelling kidney outcomes based on MELD eras-impact of MELD score in renal endpoints after liver transplantation[J]. BMC Nephrol, 2022, 23( 1): 294. DOI: 10.1186/s12882-022-02912-6.
    [16]
    YE YN, ZHANG ZQ, HE G, et al. Analysis of high-risk factors for hepatorenal syndrome in patients with hepatitis B-related acute-on-chronic liver failure[J]. Hainan Med J, 2019, 30( 24): 3145- 3149. DOI: 10.3969/j.issn.1003-6350.2019.24.004.

    叶一农, 张志侨, 何纲, 等. 乙型肝炎相关慢加急性肝衰竭患者发生肝肾综合征的高危因素分析[J]. 海南医学, 2019, 30( 24): 3145- 3149. DOI: 10.3969/j.issn.1003-6350.2019.24.004.
    [17]
    YIN W, LI CZ. Prospective study on the risk factors and the treatment response of acute renal injury in liver cirrhotic patients[J]. Chin Hepatol, 2020, 25( 8): 791- 796. DOI: 10.14000/j.cnki.issn.1008-1704.2020.08.007.

    尹伟, 李成忠. 肝硬化急性肾损伤发病风险和治疗应答影响因素的前瞻性研究[J]. 肝脏, 2020, 25( 8): 791- 796. DOI: 10.14000/j.cnki.issn.1008-1704.2020.08.007.
    [18]
    JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33( 6): 550- 558. DOI: 10.1200/JCO.2014.57.9151.
    [19]
    LEI Q, ZHANG YH, KE CZ, et al. Value of the albumin-bilirubin score in the evaluation of hepatitis B virus-related acute-on-chronic liver failure, liver cirrhosis, and hepatocellular carcinoma[J]. Exp Ther Med, 2018, 15( 3): 3074- 3079. DOI: 10.3892/etm.2018.5748.
    [20]
    ADEBAYO D, MORABITO V, DAVENPORT A, et al. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy[J]. Kidney Int, 2015, 87( 3): 509- 515. DOI: 10.1038/ki.2014.338.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (154) PDF downloads(32) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return